Purpose: To retrospectively review our experience with VNS in pediatric patients with pharmacoresistant epilepsy and examine the seizure-frequency outcome and rates of discontinuation in two age groups: adolescent and pre-adolescent children. Results: Complete pre-and post-VNS data were available for 46/49 patients. Median age at implantation was 12.1 (range 2.3-17.9) and median duration of epilepsy 8.0 (1.9-16.9) years. Twenty-one patients (45.6%) were under 12 years at the time of surgery. Median follow-up was 2 years; follow-up exceeded 4 years in 9/46 patients.
Introduction
Vagus nerve stimulation (VNS) was introduced in the U.S. in 1997 as adjunctive therapy ''in adults and adolescents over 12 years of age with partial onset seizures, which are refractory to antiepileptic medications''. Left cervical VNS remains the only form of chronic, intermittent neuroelectrical brain stimulation that has shown efficacy and safety in patients with epilepsy based on prospective, randomized controlled studies. 1, 2 The device offers a non-pharmacologic therapeutic alternative for patients with pharmacoresistant epilepsy. Several articles have reported benefit of VNS in children presenting with a variety of epilepsy syndromes. [3] [4] [5] During the pre-approval phase the manufacturer of the VNS therapy system (Cyberonics Inc., Houston, TX) sponsored two randomized, double blind, active-control trials (E03 and E05) that compared two different VNS stimulation protocols for the treatment of focal seizures in patients older than 12 years of age: high ''therapeutic'' stimulation and low ''control'' stimulation. Because no formal clinical trials have been carried out in pre-adolescent children (children who are less than 12 years old at the time of VNS implantation) the FDA has not approved the use of the device in this age group.
The two pre-approval studies had a 12-week prospective baseline assessment period, a 2-week recovery period post-VNS insertion and a 12-16 week active treatment period. Both trials had concealed randomization, blinded assessment and adequate follow-up data. However, the 3-4 months of blinded follow-up post-implantation is a rather limited period of observation, if one were to consider the paroxysmal nature of epilepsy. Consequently, the long-term effect of vagus nerve stimulators remains to be determined empirically or in uncontrolled studies.
An abundance of uncontrolled long-term followup data is available in adults. More than 50% seizure reduction was observed in 39% of patients after 15 months of high ''therapeutic'' stimulation during the open-label, non-blinded extension of E05 (XE5 trial). 6 In the open-label study by Morris and Mueller a total of 440 patients were followed for up to 3 years; more than 50% seizure reduction was observed in 43% of patients at 3 years post-implantation. 7 Similar improvements have been reported up to five 8 or more years of chronic VNS. 9 It should be emphasized that only 19 adolescents (patients between 12 and 18 years) were included in the two double-blind pre-approval studies. 10 Openlabel add-on clinical data on VNS use in children featuring various epilepsy syndromes and follow-up durations have been reported since. To this day fewer publications address the effectiveness and safety of the device in children as compared to adults. 11 This retrospective study contributes to the long-term experience of chronic VNS use in adolescent and preadolescent children.
The objectives of the study were to determine the long-term efficacy of VNS in children with pharmacoresistant epilepsy referred to a tertiary epilepsy center, to compare the efficacy in two age groups pre-adolescent children <12 years of age at the time of VNS implantation versus adolescent children >12 years of age, and to evaluate the reasons families elect to discontinue chronic VNS.
Materials and methods
A list of patients, who underwent VNS implantation at our center, was obtained from operating room records. The study was approved by the Institutional Review Board (IRB# 5701). Children and adolescents of all ages with pharmacoresistant focal or generalized epilepsy were included. The VNS therapy system was implanted by the same neurosurgeon (W.E.B.) and was programmed in the operating room in all cases.
Stimulation parameters were adjusted in line with standard medical practice for VNS implanted patients. 12 Initial stimulation parameters were (output current = 0.25 mA, frequency = 30 Hz, pulse width = 250 ms, signal on-time = 30 s and offtime = 5 min). Visits for interrogation and adjustment of the device occurred at least every 1-3 months for the first 3-6 months and every 6-12 months thereafter. The stimulus intensity was increased stepwise by 0.25 mA until 1 mA. Next, the off-time was shortened. Adjustments to signal frequency and rapid cycling were not performed routinely. The maximum current used in our patients was 2.5 mA. Antiepileptic drugs (AEDs) were typically left unchanged during the first 12 months unless adjustments were necessitated by increasing seizures or drug toxicity.
Variables included age at onset of epilepsy and at the time of VNS implantation, duration of epilepsy, seizure types and presumed cause(s), presence or absence of developmental disabilities and/or other related medical conditions, presence or absence of MRI abnormalities and results of comprehensive epilepsy evaluations. Patients' demographic and clinical characteristics divided in two groups based on their age at the time of VNS implantation are presented in Tables 1 (pre-adolescent children <12 years) and 2 (older children >12 years of age at time of VNS surgery).
All patients had at least one baseline assessment within 4-8 weeks before surgery and were followed implantation. Thereafter, seizure-frequency data were obtained from patients' regular yearly followup visits (at 2, 3 and 4 years after insertion of the VNS generator). Data from yearly follow-up appointments (at 12, 24, 36 and 48 months) were included, if patients had been seen within 1-2 months from the specified follow-up time. VNS data derived from additional VNS-related assessments (for example at 1 month post-implantation) or during routine neurology clinic and/or emergent hospital visits were not included in the analysis. Minimal follow-up was 6 months post-implantation, except for one patient who developed a post-operative wound infection and had the device explanted a few days after her 3-month post-implantation follow-up. Patient data were collected from standardized seizure-frequency forms, which were used at each VNS-related visit. Monthly seizure-frequency data were obtained from patients, parents and/or caregivers. In patients with more than one type of seizures data were collected for overall monthly seizure-frequencies. This information was entered into a database and was available for subsequent analysis.
The following outcome variables were assessed: (a) percentage change in total seizure-frequency during treatment relative to baseline, (b) seizure responder rate, i.e. percentage of patients who had at least 50% reduction in total seizure-frequency during treatment, and (c) treatment withdrawal (any reason).
Post-implantation seizure-frequency change in a non-fixed pediatric population was examined in two ways, as previously reported by Morris and Mueller 7 In the setting of declining numbers during extended periods of follow-up one type of analysis includes only data available for the corresponding time periods (declining numbers analysis). The second approach by the last-observation-carried-forward analysis (LOCF) uses the last recorded data for all patients including those exiting treatment.
Significance of seizure-frequency change after VNS implantation was assessed using the Wilcoxon signed-rank test. Tests were two-tailed with a significance level of 0.05. Seizure reductions of 50, 75 and 90% were calculated based on total seizure burden (Tables 1 and 2 ). Analysis was done with SAS 9.1 (SAS Institute, Cary, NC) and graphics were produced with R 1.8.0.
Results
Total number of VNS-related surgeries in adult and pediatric patients during the period between 12/ 16/1997 and 12/31/2003 was 190. The total number of left VNS implantations during the same period was 157; the remaining 33 VNS-related surgeries aimed to replace the battery and/or stimulator (19) or remove the device (13 patients). One patient returned to the operating room for wound debridement without removal of the stimulator.
We identified a total of 49 patients younger than 18 years among the 157 patients with intractable epilepsy, who underwent implantation of the device during the specified period. These patients did not qualify for resective epilepsy surgery or had failed previous surgical resection. Complete pre-and postoperative data were available for 46 of the 49 implanted pediatric patients.
Three patients (one preadolescent, age 10.8 years, and two adolescent children, ages 13.1 and 14.6 years at VNS implantation) were excluded from the analysis, because of brief or no postimplantation follow-up data. All 3 patients were out of state and had undergone a comprehensive presurgical evaluation at our institution prior to VNS implantation.
Median age at implantation was 12.1 years (range 2.3-17.9, S.D. = 4.3). Median age at onset of epilepsy was 1.5 years (ranging from 2 months to 13.5 years of age, S.D. = 3.4) and median duration of epilepsy (at the time of implantation) was 8.0 years (ranging from 1.9 to 16.9 years, S.D. = 3.9). Twentyone patients (45.6%) -10 girls and 11 boys -were under 12 years of age at the time of surgery ( Table 1) . The remaining 25 patients -11 girls and 14 boys -had the device implanted between the ages of 12 and 18 years ( Table 2 ). As expected there was a statistically significant difference in duration of epilepsy when comparing the two age groups (Wilcoxon rank-sum test, p = 0.05). The median duration of epilepsy was 6.04 years (S.D. = 2.7) in the pre-adolescent group (children <12 years at the time of VNS implantation); the corresponding value was significantly longer in the adolescent group: 11.25 years (S.D. = 3.4 years).
Although pre-adolescent children appeared to have an overall higher seizure burden at baseline (median seizure-frequency = 290 seizures/month) there was also a higher variability in seizure-frequencies observed in the younger group (S.D. = 2434.3). In the adolescent group median seizure-frequency was 62 seizures/month (S.D. = 1209.1). The difference in overall seizure-frequency was not statistically significant (Wilcoxon rank-sum test). Furthermore, there was no statistically significant difference (Wilcoxon rank-sum test) in the number of AEDs at the time of implantation (on average 2 AEDs, ranging from 1 to 3 in the younger and 1-4 in the older group) or the number of failed AEDs prior to VNS therapy (which ranged from 4 to 12 AEDs in either group).
A known etiology of the epilepsy was identified in 15 patients: tuberous sclerosis in 3 (6.5%) and other malformations of cortical development in 6 (13%); encephalitis and mitochondrial disorder (two each); hypothalamic hamartoma and head trauma (one each). Four patients (8.7%) carried the diagnosis of idiopathic intractable generalized epilepsy. The etiology remained unknown in the majority of patients (58.7%).
Electroencephalography with routine and prolonged video-EEG evaluations showed evidence for a focal or multifocal epilepsy in 19 patients (41.3%). The remaining 27 patients presented with a generalized epilepsy syndrome. Seizure types included generalized tonic-clonic and other generalized seizures (myoclonic, absence, and atonic seizures) and/or complex partial and focal motor seizures (Tables 1 and 2) .
Comorbidities in our patient population included mental retardation in 33 (71.7%), attention deficit hyperactivity disorder in 8 (17.4%), and presence of hemiparesis or quadriparesis in 4 (8.7%). Other less frequent comorbid conditions included learning disabilities, behavioral dyscontrol, depression, autistic spectrum disorders, oromotor apraxia, and non-epileptic seizures. Four patients (8.7%) had no identifiable comorbidities.
MRI findings consisted of malformations of cortical development in six (including focal cortical dysplasia, polymicrogyria, macrogyria and lissencephaly), cortical tubers and findings consistent with Tuberous Sclerosis Complex in three (6.5%), mild cortical atrophy in four (8.7%), and dysmorphic mesial temporal structures in three (7.4%). Other less common findings included bifrontal encephalomalacia, multiple cortical infarcts, and hypothalamic hamartoma. No structural abnormalities were evident on MRI in half of the patients (23/46).
Follow-up intervals extended to 12 months in 39/ 46, 24 months in 23, 36 months in 16 and exceeded 48 months in 9/46 patients. Median follow-up was 2 years post-implantation. Fig. 1 shows the median percent decrease in seizures as compared to baseline with 95% confidence intervals (declining numbers analysis). Fig. 2 summarizes the results presented in the previous figure (observed values based on declining numbers) and contrasts them to those obtained from a different analysis, which is based on the last-observation-carried-forward (LOCF).
As compared to baseline, median seizure-frequency reduction in the setting of declining numbers was 56% at 3 months (n = 46), 50% at 6 months (n = 45), 63% at 12 months (n = 39), 83% at 24 months (n = 23) and 74% at 36 months (n = 16). When the last observation carried forward analysis was employed median seizure-frequency reduction in the range of 60% was observed at 1, 2 and 3 years post-VNS. Specifically, the corresponding LOCF estimates of median seizure-frequency reduction were: 56% at 3 months, 50% at 6 months, 60% at 12 and at 24 months, and 59% at 36 months (Fig. 2) . Twenty-seven patients (58.7%) had >50% seizurefrequency reduction, and out of these 27 responders, 20 had >75% overall seizure-frequency reduction by their last follow-up (20/46 or 43.5% of the entire pediatric group). No response (increase or <50% reduction) was observed in 19/46 (41.3%). There was no difference in the number of AEDs used before and after VNS (Wilcoxon rank-sum test, p = 0.05) neither in the entire cohort of 46 children nor in the two subgroups of adolescent and preadolescent children. Both adolescent and pre-adolescent children benefited from VNS implantation. However, younger patients (implanted before the age of 12 years) appeared to respond even better to VNS, when compared to the older group of pediatric patients (Fig. 1) . Statistical comparison of median reduction in overall seizure-frequencies favored the preadolescent group at 12 and 24 months of followup (Wilcoxon rank-sum, p = 0.05). A trend towards a better response was present at 36 and 48 months despite the decrease in sample size. The difference in VNS response was not significant early on (at the 3 and 6 month intervals). At their last follow-up visit none of the 25 adolescents were free of seizures. However, five pre-adolescent children had been seizure-free for a period of at least 6 months, when assessed at their last follow-up visit (Tables 1 and 2) .
Similar VNS stimulation parameters were used in both adolescent and preadolescent children. In this series pulse width was set at 250 ms and stimulus frequency at 30 Hz in all patients. The two commonly modified parameters, output current and on/ off-time (''duty cycle''), served to subdivide our patients to the following groups, as proposed by Labar. 13 First, based on the intensity of output current we identified three groups of patients: low (L) = 0.25-1 mA, medium (M) = 1.25-2 mA, and high (H) 2.25 mA, and second based on the duration of the stimulus (''duty cycle'') we considered two groups: ''standard'' (Std) cycling was defined as off-times 3 min, and ''rapid'' (Rpd) cycling as off-times 1.8 min.
At the end of follow-up the vast majority of patients were receiving standard cycling. ''Rapid'' cycling was tried without success in three adolescent (3 out of 25) and three preadolescent (3 out of 21) children, who had failed ''standard'' VNS cycling. In the adolescent group standard cycling was administered to 15 patients using medium current intensity (Std-M), to 5 using low (Std-L) and to 2 patients using high current intensity (Std-H). In the preadolescent children receiving standard cycling the corresponding numbers were Std-M = 12, Std-L = 5 children, and Std-H = 1 child. There were no significant differences between the preadolescent and adolescent group with respect to these stimulation parameters.
Among this cohort six patients required replacement of the generator's battery within 2.5-4 years after initial implantation (Tables 1 and 2) . Furthermore, a total of five patients developed a wound infection around the device (within 1 week to 6 months after implantation). Conservative treatment with intravenous antibiotics was effective in one Long-term results with vagus nerve stimulation in children with pharmacoresistant epilepsy 499 patient with post-operative wound infection ( Table 2 ). The rate of deep infections necessitating device removal in this series of pediatric patients was 7.7% (4 of 46 patients who had undergone 52 implantation or battery/generator replacement procedures). Only one out of these 4 explanted generators was subsequently replaced (1 year later-- Table 1 ). Another six stimulators were turned off within 1-3.5 years after implantation because of the absence of clinical benefit; three of these were eventually removed (Tables 1 and 2 ). In addition, one family elected not to replace the generator at the end of its battery's service. Finally, one patient insisted on using the device exclusively on-demand (he stated that magnet activation during seizures decreased their duration and severity). This data combined brings the VNS discontinuation rate in our series to 21.7% (10/46 patients). It should be noted that three patients in this series died during the period of observation: two died of probable SUDEP, the other died following surgery unrelated to VNS.
Several patients (56.5%) experienced stimulation-induced symptoms (throat pain, hoarseness, cough, drooling) that did not require device removal. These symptoms were usually mild and transient, and only limited changes of the generator's stimulation settings in 3/46 patients (6.5%). There were no cases of lead fracture.
Discussion
In this retrospective study seizure-frequency outcomes following VNS implantation and reasons for VNS discontinuation in children with generalized and focal pharmacoresistant epilepsy were assessed. VNS was well-tolerated and effective. In line with previous open-label and uncontrolled studies the observed decrease in seizure-frequency in our pediatric population improved over the first year of chronic VNS.
14 Furthermore, long-term efficacy was sustained beyond the first 1-2 years of therapy.
Our results in pediatric patients are in agreement with previous studies demonstrating efficacy in children. However, a more favorable response to chronic VNS in children younger than 12 years as compared to adolescents (12 years or older) has not been reported in large pediatric series. 3, [15] [16] [17] In general, there are fewer publications of the effectiveness of VNS in children as compared to adults with pharmacoresistant epilepsy, 11 and most reports of pediatric VNS, similar to our series, have included a heterogeneous population with both focal and generalized seizure disorders and variable periods of follow-up.
The first large VNS pediatric epilepsy series was reported in 1999 and described the results of at least 3 months of VNS treatment in 60 patients (<18 years of age) enrolled in three different multicenter trials. In the setting of declining numbers a median reduction in seizure-frequency of 23% at 3 months, 31% at 6, 34% at 12 and 42% at 18 months was observed. This study included 16 children younger than 12 years of age, enrolled in a compassionate use uncontrolled pre-approval trial. Although these younger children had more severe seizures than the older ones they appeared to derive a benefit similar to that of the entire group. 3 More recently 6 centers participated in a large retrospective series of 125 pediatric patients (<18 years of age) who had been treated with VNS for a limited period ranging from 3 months to 1 year. Average seizure reduction was 36.1% at 3 months and 44.7% at 6 months. The authors did not observe any difference in seizure reduction among the group of 41 patients younger than 12 years at the time of VNS implantation. 17 examined seizure-frequency and quality of life outcomes in 38 consecutive pediatric patients. At a median followup period of 12 months seizure reduction greater than 50% was achieved in 26/38 patients (68%). There was no difference in the response observed in the younger (<12 years at implantation, n = 28) as compared to the older pediatric patients.
The second study 15 examined the outcome in the first 100 patients implanted at a single pediatric epilepsy center; 28 patients in this group had participated in the pre-approval VNS trials. Twelve patients were older than 18 years at the time of implantation. At a mean follow-up period of 2.7 years seizure reduction greater than 50% was achieved in 45% of patients. Of note 18% of patients in this series were seizure-free for 6 months at their last follow-up. The authors reported similar percentages of seizure-frequency reduction in younger (6-11 years of age; n = 50) and older patients (12) (13) (14) (15) (16) (17) (18) years of age at the time of VNS implantation; n = 34).
The reason our pre-adolescent children had greater seizure reductions compared with published reports is not clear. The two age groups did not differ in terms of overall seizure-frequency, VNS stimulation parameters, number of failed AEDs, number of AEDs at the time of VNS implantation, or number of AEDs during the period of chronic VNS. All children in this series were followed closely for at least 6 months after VNS implantation. There was no difference between the two groups in terms of frequency of VNS adjustment, and as expected, pre-adolescent children had a shorter duration of epilepsy.
The apparent greater efficacy of VNS in this group may implicate mechanisms related to brain plasticity and/or earlier use of the device. 18 However, it should be emphasized that these observations are uncontrolled and that the influence of maturation or other extraneous effects cannot be excluded. Another variable is the frequency of stimulator adjustments following implantation. Patients in this series were followed closely and at regular intervals post-VNS implantation. It is possible that this entire cohort of pediatric patients underwent more frequent and more regular VNS adjustments as compared to VNS adjustments reported in other studies. Other investigators have suggested that children with highly medication-resistant seizures, such as children with Lennox-Gastaut in particular, may derive significant benefit from VNS. 10, 19, 20 VNS is usually not associated with the common central nervous system adverse effects that sometimes limit use of AEDs (such as dizziness, ataxia, insomnia, cognitive impairment, weight gain or sexual dysfunction). Moreover most patients become accustomed to stimulation-related side effects, which tend to diminish over time. In our study VNS-related adverse effects were mild and transient and only limited changes of the generator's stimulation settings in three patients.
Complications associated with implantation have included infection at the incision, lead fractures and transient paralysis of the left vocal cord. 21, 22 The VNS discontinuation rate in our series was 21.7% (10/46 patients) and primarily reflected the absence of clinical response after 12 months or more of intermittent VNS. Five of our patients developed a wound infection around the generator, which necessitated device removal in four. Incisional infection was present in the immediate post-operative period in 3/5 patients. The other two, who were not compliant with instructions for proper wound care, developed signs of infection 3-6 months after surgery (Tables 1 and 2 ). The overall rate of deep infections necessitating device removal in this series of pediatric patients was 7.7% (4/52 patients who had undergone implantation or battery/generator replacement procedures). Such infections requiring explantation may be more common in younger age children, especially those with mental retardation. 23 Frequent drooling resulting to saliva/food soiling of the incision, and/or picking at the incision and inadvertent wound manipulation are not uncommon occurrences in this population and may account for the higher infection rate. In this series severe developmental delay was present in three of the four patients, who had the device removed because of infection.
This study has inherent limitations because of its retrospective, uncontrolled nature (class IV). 24 Furthermore, patient assessment in this series was not blinded and seizure-frequency data was based on reporting by patients and/or families. Indeed, the post-approval VNS literature suffers from the lack of randomized controlled trials examining longer-term outcomes. Evidence-based decisions in both adult and pediatric VNS candidates remain complicated, in part due to the narrow scope of the initial randomized control studies of VNS (which were limited to patients aged 13-60 years, who had drug-resistant focal epilepsy, and only examined the median seizure-frequency reduction over a 3-month treatment period). 25 This limited evidence from randomized trials should be complemented by long-term studies that reflect everyday clinical practice. Non-randomized longer-term studies (>6 months) suggest that the effect of VNS may improve with time. 7, 26 At this time, however the weight of evidence that supports the use of VNS in pre-adolescent children is weak, 27 despite promising results from studies similar to ours. We agree with previous investigators who prompt us to interpret these results with caution ''because of the uncontrolled, open-label design, enrollment of patients who have a variety of epilepsy syndromes; differing lengths of follow-up, and the varied and changeable antiepileptic medications coadministered''.
14 Finally, we cannot speculate on the net benefit of intermittent VNS without a non-stimulated control group.
Quality of life (QOL) indicators were not examined in this study. The VNS outcome registry maintained by the manufacturer captures open-label clinical data including seizure control and QOL parameters (alertness, verbal communication, memory, school/professional achievement, mood, postictal state, and seizure clustering), which are collected by physicians on a voluntary basis. Despite the integral biases in selection, assessment and reporting of subjects enrolled in the registry, this data suggest that chronic VNS may lead to improvement in QOL domains. 28 A few pediatric VNS series indicate that VNS improves QOL in treated children. Of note, it has been suggested that improvement in quality of life (QOL) may be independent from the antiseizure effect of VNS. In a series of 16 Lennox Gastaut patients the best improvement in QOL was seen in patients, who did not benefit from the VNS in terms of seizure-frequency reduction. 29 In another series of patients with autism and Landau-Kleffner syndrome improvements in QOL were seen in up to 76% of pediatric patients at 12 months of follow-up. 30 These studies utilize variable QOL assessment tools and have limitations inherent to their open-label addon designs. 17, 31 Chronic vagus nerve stimulation shows promise, when used as adjunctive therapy in children with medically intractable (focal and/or generalized) epilepsy. Because of its non-pharmacologic nature this therapy is devoid of the frequent adverse and interactive effects encountered with AED polypharmacy in the vulnerable pediatric population. We conclude that the use of VNS in children merits further investigation in a randomized controlled fashion, but at the same time the limited available evidence supports its continued use in pre-adolescent and adolescent children. Future research using economic decision analysis could help determine whether the potential benefits are worth the additional cost (removal of infected generator, need for battery changes) in a pediatric population. In the meantime, empiric evidence similar to ours suggests that chronic VNS should be considered for the treatment of children younger than 12 years of age, as they appear to respond as well or even better than adolescent children with pharmacoresistant epilepsy.
